Identifying Novel Targets by using Drug-binding Site Signature: A Case Study of Kinase Inhibitors
Type
PreprintKAUST Department
Biological and Environmental Sciences and Engineering (BESE) DivisionBioscience Program
Computational Bioscience Research Center (CBRC)
Computer Science Program
Computer, Electrical and Mathematical Sciences and Engineering (CEMSE) Division
Structural Biology and Engineering
Structural and Functional Bioinformatics Group
KAUST Grant Number
FCC/1/1976-25Date
2019-12-02Permanent link to this record
http://hdl.handle.net/10754/664280
Metadata
Show full item recordAbstract
AbstractCurrent FDA-approved kinase inhibitors cause diverse adverse effects, some of which are due to the mechanism-independent effects of these drugs. Identifying these mechanism-independent interactions could improve drug safety and support drug repurposing. We have developed “iDTPnd”, a computational approach for large-scale discovery of novel targets for known drugs. For a given drug, we construct a positive and a negative structural signature that captures the weakly conserved structural features of drug binding sites. To facilitate assessment of unintended targets iDTPnd also provides a docking-based interaction score and its statistical significance. We were able to confirm the interaction of sorafenib, imatinib, dasatinib, sunitinib, and pazopanib with their known targets at a sensitivity and specificity of 52% and 55% respectively. We have validated 10 predicted novel targets, using in vitro experiments. Our results suggest that proteins other than kinases, such as nuclear receptors, cytochrome P450 or MHC Class I molecules can also be physiologically relevant targets of kinase inhibitors. Our method is general and broadly applicable for the identification of protein-small molecule interactions, when sufficient drug-target 3D data are available.Citation
Naveed, H., Reglin, C., Schubert, T., Gao, X., Arold, S. T., & Maitland, M. L. (2019). Identifying Novel Targets by using Drug-binding Site Signature: A Case Study of Kinase Inhibitors. doi:10.1101/860510Sponsors
The authors thank Dr. Aly Azeem Khan for helpful discussions. This work has been supported by the Toyota Technological Institute at Chicago, King Abdullah University of Science and Technology and a grant to establish Precision Medicine Lab under the umbrella of National Center in Big Data & Cloud Computing from the Higher Education of Pakistan. The research by STA reported in this publication was supported by funding from King Abdullah University of Science and Technology (KAUST), Office of Sponsored Research (OSR), under award number FCC/1/1976-25.Publisher
Cold Spring Harbor LaboratoryDOI
10.1101/860510Additional Links
http://biorxiv.org/lookup/doi/10.1101/860510https://www.biorxiv.org/content/biorxiv/early/2019/12/01/860510.full.pdf
ae974a485f413a2113503eed53cd6c53
10.1101/860510
Scopus Count
Collections
Biological and Environmental Sciences and Engineering (BESE) Division; Preprints; Bioscience Program; Structural and Functional Bioinformatics Group; Computer Science Program; Computational Bioscience Research Center (CBRC); Computer, Electrical and Mathematical Sciences and Engineering (CEMSE) Division
Except where otherwise noted, this item's license is described as Archived with thanks to Cold Spring Harbor Laboratory